Including Expanded Profound AI Platform at RSNA Annual Meeting
iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced it will showcase its Breast Health Solutions suite including the expanded ProFound AI™ platform in the iCAD exhibition booths (#3929 in the south hall and #10716 in the north hall) at the Radiological Society of North America (RSNA) Annual Meeting in Chicago, December 1-6, 2019.
iCAD’s Breast Health Solutions suite includes ProFound AI for Digital Breast Tomosynthesis (DBT), the first artificial intelligence (AI) software for DBT to be FDA-cleared, as well as software solutions for 2D mammography and breast density. During the meeting, the Company will also unveil its vision for future technologies, including solutions that will enable clinicians to more easily consider patients’ prior images* and prospective breast cancer risk assessment over time.*
“ProFound AI has extensive potential in the realm of clinical AI and in the future it will offer a more holistic clinical approach that can provide clinicians with a broader view of each individual patient’s case, history, and short-term risk,” said Michael Klein, Chairman and CEO of iCAD. “Today, ProFound AI offers clinically-proven improvements in sensitivity, specificity, time-savings and recall rates, but our panoramic vision for the future will include innovative tools that allow physicians to correlate findings across time and provide more tailored and personalized patient care.”
Trained with one of the largest available DBT datasets, ProFound AI rapidly and accurately analyzes each DBT image, or slice, and provides radiologists with key information, such as Certainty of Finding lesion and Case Scores, which assists in clinical decision-making and improving reading efficiency. Featuring the latest in deep-learning artificial intelligence, the algorithm allows for continuously improved performance via ongoing updates.
Clinical data from a large reader study involving ProFound AI for DBT were recently published in Radiology: Artificial Intelligence. According to study findings, ProFound AI for DBT improved radiologist sensitivity by 8 percent, reduced unnecessary patient recall rates by 7.2 percent, and slashed reading time for radiologists by 52.7 percent.1 Additionally, ProFound AI cut reading time by up to 57.4 percent for radiologists reading cases of women with dense breasts.2
Results from a subgroup analysis of this reader study examining improvement in accuracy and reading times for traditional 2D mammography will be presented during the meeting on Sunday, December 1 by Emily F. Conant, M.D., professor and chief of breast imaging from the Department of Radiology at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia. According to study findings, ProFound AI improved sensitivity and specificity and reduced reading time for radiologists reading DBT with digital or with synthetic 2D.
“Our reader study demonstrated that the concurrent use of AI improved sensitivity, specificity and reading time when reading DBT with digital or synthetic 2D images,” according to Dr. Conant, principal investigator and lead author of the study. “These findings show improved cancer detection benefiting our patients as well as improved efficiency important for radiologists.
Events and clinical presentations throughout the meeting will feature experts who can discuss clinical perspectives and experience using ProFound AI in daily practice:
- Monday, December 2: An investor luncheon and an evening reception, “AI After Dark,” will feature leading experts who will provide real-world experience and clinical perspectives in breast health solutions powered by artificial intelligence. The investor luncheon will be webcast and available online via this link.
- Tuesday, December 3: Innovation Theater Presentation, “Advances in AI for personalized breast cancer screening using image-based short-term risk assessment,” will be presented by Mikael Eriksson, PhD, Karolinska Institutet.
- Wednesday, December 4: AI Theater Presentation, “Advancements in Mammography for Cancer Detection and Risk Prediction” will be presented by Senthil Periaswamy, PhD, Chief Research Scientist, VP of Clinical Innovation, iCAD, Inc.
Leading experts will also be available in the main iCAD booth (#3929 in the south hall) daily throughout the meeting to offer live demonstrations with the technology. ProFound AI will also be featured in major PACS company exhibits at the meeting.